Union Health Minister JP Nadda highlighted the crucial role of Indian generic drugs in treating malaria, HIV-AIDS, and tuberculosis in developing countries. He made this statement during the inauguration of the ‘First Policy Makers’ Forum’ in the national capital, which will continue until August 22.
Nadda emphasized that India, recognized as the ‘pharmacy of the world,’ is proud of its role in providing affordable medications. He noted that these high-quality generic drugs are essential for treating diseases prevalent in developing nations.
The minister underscored India’s commitment to eradicating these diseases. He stated, “This contribution highlights India’s dedication to global health and our responsibility in addressing the healthcare gap in developing countries.”
Nadda also addressed the high cost of HIV-AIDS medications, explaining that Indian manufacturers lead the way in offering effective and affordable drugs. This effort significantly alleviates the financial burden on developing nations.
Also Read: Udaipur Stabbing Case: Teen’s Last Rites Held Under Heavy Security Amid Tensions
Regarding vaccines, Nadda pointed out that India is a global leader in production and supply. He revealed that India provides about 60 percent of the world’s vaccines. He also said that the World Health Organization (WHO) sources 70 percent of its vaccine needs from India.
The minister also mentioned India’s Vaccine Maitri Programme, which supplied vaccines to numerous countries during the Covid-19 pandemic.
At the forum, Nadda introduced key health initiatives, including the Jan Aushadhi Scheme. This scheme aims to provide high-quality medicines at affordable prices, especially to the underprivileged. Additionally, he highlighted the Ayushman Bharat scheme. Ayushman Bharat scheme offers health insurance coverage for over 500 million people, with a coverage amount of $6,000.
Nadda noted that India is collaborating with various countries in the health and pharma sectors to enhance global health. The forum featured an international delegation of policymakers and drug regulators from 15 countries. It also included the launch of innovative digital platforms for pharmacopeia and drug safety monitoring.
Nadda described the forum as an “excellent opportunity” to discuss the safety, efficacy, and quality of medical pharmaceutical products with global partners.
